Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

Y. Benhamou, Marie-Valérie Bochet, Vincent Thibault, +9

The Lancet

Open-label Pilot StudyViral HepatitisMedicineAntiviral Drug DevelopmentHepatitis B +8

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults

JK Rockstroh, Sanjay Bhagani, Y. Benhamou, +6

HIV Medicine

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

Thierry Poynard, Philippe Halfon, Laurent Castéra, +6

Clinical Chemistry

Treatment of AIDS-Associated Gastrointestinal Cytomegalovirus Infection with Foscarnet and Ganciclovir: A Randomized Comparison

C Blanshard, Y. Benhamou, Elisabeth Dohin, +3

The Journal of Infectious Diseases

Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation

Thierry Poynard, Philippe Halfon, Laurent Castéra, +8

Alimentary Pharmacology & Therapeutics

Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status

Philippe Halfon, Marc Bourlière, Stanislas Pol, +13

Journal of Viral Hepatitis

10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS

Y. Benhamou, J. Moussalli, Vlad Ratziu, +8

Journal of Hepatology

Hcv PatientsViral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitis +3

751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results

Y. Benhamou, Paul J. Pockros, M. Rodrieuez-Torres, +7

Journal of Hepatology

Viral HepatitisImmunologyAntiviral Drug DevelopmentHepatitisVirology +7

58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY

G Dusheiko, Christophe Hézode, Stanislas Pol, +16

Journal of Hepatology

HepatologyHepatitis CThe Prove2 StudyViral HepatitisAntiviral Drug Development +6

1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL

J.‐P. Bronowicki, Christophe Hézode, Leif Bengtsson, +15

Journal of Hepatology

NeurovirologyImmunodeficienciesViral HepatitisImmunologyClinical Trials +7